Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
about
Systemically Administered, Target Organ-Specific Therapies for Regenerative MedicineCD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent modelImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAExpression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.Early gestational gene transfer of IL-10 by systemic administration of lentiviral vector can prevent arthritis in a murine model.Lactobacillus acidophilus Protected Organs in Experimental Arthritis by Regulating the Pro-inflammatory Cytokines3D domain swapping causes extensive multimerisation of human interleukin-10 when expressed in planta.Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potencyA highly functional synthetic phage display library containing over 40 billion human antibody clones.Radiation damage and radioprotectants: new concepts in the era of molecular medicineMatricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationImmunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.Immunocytokines for cancer treatment: past, present and future.Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.Monoclonal antibody treatments for rheumatoid arthritis.Latent cytokines for targeted therapy of inflammatory disorders.The dual nature of interleukin-10 in pemphigus vulgaris.Trojan horses and guided missiles: targeted therapies in the war on arthritis.Therapeutic potential of regulatory cytokines that target B cells.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.Progress and clinical potential of antibody-targeted therapy for arthritic damage.Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?A matrix metalloproteinase 1-cleavable composite peptide derived from transforming growth factor β-inducible gene h3 potently inhibits collagen-induced arthritis.8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
P2860
Q26782082-28ADD849-01AB-49C7-8EA2-F95E376AFE18Q27318165-F76AB45D-94B1-4C37-8C75-76787595A872Q28066935-858EA1AF-4B8B-439F-BDCB-4CCEE38BD5D2Q28660580-8A0B95D5-78C4-4346-A791-A30D7A2D50D3Q33605532-EB67D1B6-E014-4CC3-962F-FA7C053FD3B2Q33870905-BCA74A79-8174-4A5E-BFBF-F2AC206766B5Q34072266-6E84EBF4-29F0-441A-A48D-7FC6FEE4BB67Q34083054-81718FB6-7482-40DF-B0A3-BAEFC0891E15Q34169584-8DFABD2C-FEF7-4483-80F8-5E5CCDE53DCDQ34246868-C3B859FB-511E-40B9-B452-229C2486B7CEQ34437671-C9B139B8-5AAB-4204-BEE2-54D2AD1ED182Q34478537-5D4D0350-866F-4921-8C4B-7D644E0D3730Q35192223-4BF436F7-C55B-4904-B1BC-058DB2D660FCQ36364394-0B40802F-62F8-4409-BCB4-026FD105A0FDQ36578825-4DA98711-E322-4682-9E3C-1E06E1BA4CE2Q37485709-87C66142-E9C2-4FCC-9D17-3A742A17C970Q37559740-B1B3C994-D888-498E-A4BC-382BC5D3CD3DQ37560208-CE3839DE-BD92-4CD7-8D23-275D8C7F256EQ37690616-E28DF475-CFA7-49C8-9DCD-2BAFAA1ADFFCQ38116065-1394E357-83EE-4437-9DD1-9872A666771AQ38167818-F3E7523E-242F-4B0E-B1BE-DED6AB329C69Q38281273-1F864414-45B6-4F2F-B9C3-47FF5C2083D0Q38367194-DEFB27B7-184A-4F05-B171-F13AD6E724CDQ38662898-A12EADE6-B184-420B-B869-DB930877FAE1Q38988662-EC201062-268A-4372-A431-2B5326E78469Q39159292-0248E56C-8F55-48AE-B374-03CF71819E4CQ39185087-2FE7D320-E95A-4EA6-9966-0FCEE64A9024Q39609067-6780A110-FCC0-4E13-83F3-41B410FCE875Q40561232-BAE3F955-F950-4DFD-AB5B-161CF34CA8F8Q40646856-7AC89C92-F632-41E4-BCEB-D26C5880216FQ42489583-7093B15B-E6F8-405F-BBD5-61BB7B32A2BBQ42544262-C21ABD01-593F-4285-BC65-B0EFA85871B9Q42824423-69682BFA-BD9F-4AEC-B34C-0D8F0DF4063AQ42906644-E49A9934-5238-46E5-AFE8-02FF0B771C67Q45225869-A8B62093-4D1B-45FB-979D-1408ABFBA9D4Q47277628-E3261B8F-3869-4B22-A480-7A378A8E5C66Q49819157-02E30E26-6D8D-426C-B575-611B9BBA8993Q50039410-85AE662D-B0BC-4D90-9DD8-0C3A1676A8F7Q50592781-50218433-7583-44C2-A7F0-F8FEFC80E299Q50864449-4D6E687D-E79C-420D-A434-563CC138897D
P2860
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical characterization o ...... of collagen-induced arthritis.
@en
Preclinical characterization o ...... of collagen-induced arthritis.
@nl
type
label
Preclinical characterization o ...... of collagen-induced arthritis.
@en
Preclinical characterization o ...... of collagen-induced arthritis.
@nl
prefLabel
Preclinical characterization o ...... of collagen-induced arthritis.
@en
Preclinical characterization o ...... of collagen-induced arthritis.
@nl
P2093
P2860
P356
P1476
Preclinical characterization o ...... of collagen-induced arthritis.
@en
P2093
Erberto Paresce
Eveline Trachsel
Frank Bootz
Kathrin Schwager
Manuela Kaspar
Roberto Marcolongo
P2860
P2888
P356
10.1186/AR2814
P50
P577
2009-09-25T00:00:00Z